AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Ubiquitin/ISG15-conjugating enzyme E2 L6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O14933

UPID:

UB2L6_HUMAN

Alternative names:

E2 ubiquitin-conjugating enzyme L6; Retinoic acid-induced gene B protein; UbcH8; Ubiquitin carrier protein L6; Ubiquitin-protein ligase L6

Alternative UPACC:

O14933; A6NDM6; A8MY53; Q8N5D8; Q9UEZ0

Background:

Ubiquitin/ISG15-conjugating enzyme E2 L6, known by alternative names such as E2 ubiquitin-conjugating enzyme L6 and UbcH8, plays a crucial role in protein regulation. It catalyzes the covalent attachment of ubiquitin or ISG15 to other proteins, including the E6/E6-AP-induced ubiquitination of p53/TP53 and promotes the ubiquitination and subsequent proteasomal degradation of FLT3.

Therapeutic significance:

Understanding the role of Ubiquitin/ISG15-conjugating enzyme E2 L6 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.